Date | Price Target | Rating | Analyst |
---|---|---|---|
8/29/2024 | $131.00 → $159.00 | Neutral → Overweight | Piper Sandler |
4/24/2024 | $140.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
12/13/2023 | $127.00 | Neutral | Citigroup |
12/12/2023 | $136.00 | Buy | Deutsche Bank |
10/24/2023 | $135.00 → $140.00 | Overweight | Cantor Fitzgerald |
8/21/2023 | $112.00 → $113.00 | Neutral | Mizuho |
7/24/2023 | $115.00 → $125.00 | Market Perform → Outperform | SVB Securities |
7/6/2023 | $91.00 → $96.00 | Underperform → Market Perform | BMO Capital Markets |
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
S-8 - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
10-Q - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baselineThe once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in Clinica
The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from BaselineThe Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom ChangeNBI-'568 Was Generally Safe and Well Tolerated at All Doses StudiedThe Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025Company
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its 2024 financial guidance. "At Neurocrine, we are energized by the tremendous opportunity we see to help many
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled SubjectsNeurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for Major Depressive DisorderSAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential
SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m. Eastern Time on Tuesday, September 17, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at the conference. The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be a
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will present at two upcoming investor conferences in September. Chief Executive Officer Kevin Gorman, Chief Business Development and Strategy Officer Kyle Gano, and Chief Financial Officer Matt Abernethy will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York at 3:20 p.m. Eastern Time on Wednesday, September 4, 2024.K
Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $155 price target.
Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
Piper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously
Wells Fargo upgraded Neurocrine Biosciences from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
Citigroup resumed coverage of Neurocrine Biosciences with a rating of Neutral and set a new price target of $127.00
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.
SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Her strong track record in leadership positions at some of the most established global biopharmaceutical enterprises will serve Neurocrine well." Ms. Poon has demonstrated br
SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021. "Ingrid's deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)